In contrast to CAR therapy, GML TCR therapy offers access to certain tumor-specific targets, particularly due to its ability to recognize intracellular proteins presented as peptides in the context of the major histocompatibility complex (pMHC). The gene discussed is GML; the disease is neoplasm.